Marc W. Fariss
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marc W. Fariss has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Andrew R. Joyce
Scientific Division, RemX Inc., Richmond, VA 23219, USA
1 shared publication Hans-Juergen Haussmann
A Toxicology Consultant , Roesrath , Germany
1 shared publication- Peter Nicholas Lee
P.N. Lee Statistics and Computing Ltd., Sutton, UK
1 shared publication Tapas K. Sengupta
Altria Client Services, Health and Analytical Sciences, 601 East Jackson Street, Richmond, VA 23219, USA
1 shared publicationWilliam Hawkins
Scientific Division, RemX Inc., Richmond, VA 23219, USA
1 shared publication
Latest Publications
- Open Access
- 3 October 2016
- Published by Springer Nature in Archives of Toxicology
- Vol. 91 (4) , 1565-1594
A systematic review of possible serious adverse health effects of nicotine replacement therapy
We conducted a systematic literature review to identify and critically evaluate studies of serious adverse health effects (SAHEs) in humans using nicotine replacement therapy (NRT) products. Serious adverse health effects refer to adverse events, leading to substantial disruption of the ability to conduct normal life functions. Strength of evidence evaluations and conclusions were also determined for the identified SAHEs. We evaluated 34 epidemiological studies and clinical trials, relating NRT use to cancer, reproduction/development, CVD, stroke and/or other SAHEs in patients, and four meta-analyses on effects in healthy populations. The overall evidence suffers from many limitations, the most significant being the short-term exposure (≤12 weeks) and follow-up to NRT product use in most of the studies, the common failure to account for changes in smoking behaviour following NRT use, and the sparse information on SAHEs by type of NRT product used. The only SAHE from NRT exposure we identified was an increase in respiratory congenital abnormalities reported in one study. Limited evidence indicated a lack of effect between NRT exposure and SAHEs for CVD and various reproduction/developmental endpoints. For cancer, stroke and other SAHEs, the evidence was inadequate to demonstrate any association with NRT use. Our conclusions agree with recent statements from authoritative bodies.
- 3 October 2016
- Published by Springer Nature in Archives of Toxicology
- Vol. 91 (4) , 1565-1594
Open AccessA systematic review of possible serious adverse health effects of nicotine replacement therapy
We conducted a systematic literature review to identify and critically evaluate studies of serious adverse health effects (SAHEs) in humans using nicotine replacement therapy (NRT) products. Serious adverse health effects refer to adverse events, leading to substantial disruption of the ability to conduct normal life functions. Strength of evidence evaluations and conclusions were also determined for the identified SAHEs. We evaluated 34 epidemiological studies and clinical trials, relating NRT use to cancer, reproduction/development, CVD, stroke and/or other SAHEs in patients, and four meta-analyses on effects in healthy populations. The overall evidence suffers from many limitations, the most significant being the short-term exposure (≤12 weeks) and follow-up to NRT product use in most of the studies, the common failure to account for changes in smoking behaviour following NRT use, and the sparse information on SAHEs by type of NRT product used. The only SAHE from NRT exposure we identified was an increase in respiratory congenital abnormalities reported in one study. Limited evidence indicated a lack of effect between NRT exposure and SAHEs for CVD and various reproduction/developmental endpoints. For cancer, stroke and other SAHEs, the evidence was inadequate to demonstrate any association with NRT use. Our conclusions agree with recent statements from authoritative bodies.
- Open Access
- 9 June 2016
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 46 (8) , 701-734
Comprehensive review of epidemiological and animal studies on the potential carcinogenic effects of nicotineper se
The effects of long-term use of nicotine per se on cancer risk, in the absence of tobacco extract or smoke, are not clearly understood. This review evaluates the strength of published scientific evidence, in both epidemiological and animal studies, for the potential carcinogenic effects of nicotine per se; that is to act as a complete carcinogen or as a modulator of carcinogenesis. For human studies, there appears to be inadequate evidence for an association between nicotine exposure and the presence of or lack of a carcinogenic effect due to the limited information available. In animal studies, limited evidence suggests an association between long-term nicotine exposure and a lack of a complete carcinogenic effect. Conclusive studies using current bioassay guidelines, however, are missing. In studies using chemical/physical carcinogens or transgenic models, there appears to be inadequate evidence for an association between nicotine exposure and the presence of or lack of a modulating (stimulating) effect on carcinogenesis. This is primarily due to the large number of conflicting studies. In contrast, a majority of studies provides sufficient evidence for an association between nicotine exposure and enhanced carcinogenesis of cancer cells inoculated in mice. This modulating effect was especially prominent in immunocompromized mice. Overall, taking the human and animal studies into consideration, there appears to be inadequate evidence to conclude that nicotine per se does or does not cause or modulate carcinogenesis in humans. This conclusion is in agreement with the recent US Surgeon General’s 2014 report on the health consequences of nicotine exposure.
- 9 June 2016
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 46 (8) , 701-734
Open AccessComprehensive review of epidemiological and animal studies on the potential carcinogenic effects of nicotineper se
The effects of long-term use of nicotine per se on cancer risk, in the absence of tobacco extract or smoke, are not clearly understood. This review evaluates the strength of published scientific evidence, in both epidemiological and animal studies, for the potential carcinogenic effects of nicotine per se; that is to act as a complete carcinogen or as a modulator of carcinogenesis. For human studies, there appears to be inadequate evidence for an association between nicotine exposure and the presence of or lack of a carcinogenic effect due to the limited information available. In animal studies, limited evidence suggests an association between long-term nicotine exposure and a lack of a complete carcinogenic effect. Conclusive studies using current bioassay guidelines, however, are missing. In studies using chemical/physical carcinogens or transgenic models, there appears to be inadequate evidence for an association between nicotine exposure and the presence of or lack of a modulating (stimulating) effect on carcinogenesis. This is primarily due to the large number of conflicting studies. In contrast, a majority of studies provides sufficient evidence for an association between nicotine exposure and enhanced carcinogenesis of cancer cells inoculated in mice. This modulating effect was especially prominent in immunocompromized mice. Overall, taking the human and animal studies into consideration, there appears to be inadequate evidence to conclude that nicotine per se does or does not cause or modulate carcinogenesis in humans. This conclusion is in agreement with the recent US Surgeon General’s 2014 report on the health consequences of nicotine exposure.
- 1 October 2010
- Published by Elsevier in Toxicology Letters
- Vol. 198 (2) , 191-199
Role of plasma membrane disruption in reference moist smokeless tobacco-induced cell death
- 1 October 2010
- Published by Elsevier in Toxicology Letters
- Vol. 198 (2) , 191-199
Role of plasma membrane disruption in reference moist smokeless tobacco-induced cell death